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Background: Determining eligibility for a kidney transplant is one of the most important decisions facing
nephrologists. It is assumed that the harm of kidney transplantation is minimal and most will benefit. The purpose
of this study was to quantify the probability of ‘no benefit’ as defined by death on the wait list; ‘harm’, defined by
the probability that a transplanted patient would live less than the average wait listed patient; and ‘benefit’ for the
probability a transplanted patient would outlive the average wait listed patient.
Methods: A computerized model was developed to replicate observed patient survival outcomes in deceased
donor kidney transplantation. Three sequential periods of risk for the transplanted recipient compared to the wait
listed cohort (increased, equivalent and reduced risk) were modeled.
Results: The model predicted that wait listed patients with a baseline mortality of 28 deaths per 100 patient years
were equally likely to benefit or be harmed with a transplant. However if 20% of patients on the wait list were on
hold (assuming a 2.2-fold higher mortality than those who were transplanted), then the baseline mortality rate for
equal harm or benefit decreases to 22 deaths per 100 patient years (equivalent life expectancy 4.5 years).
Conclusion: Patients with limited life expectancies are more likely to suffer some harm than derive benefit from
kidney transplantation.
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Much has been written about the principles of allocating
deceased kidney organs to those on the wait list. Less
has been written about ethical principles of wait list eligi-
bility. There are several principles that seem reasonable,
namely, exclusion of patients who do not want a trans-
plant (autonomy), exclusion of patients where the oper-
ation or immunosuppression are likely to cause greater
harm (non-maleficence), and exclusion of patients not
likely to benefit in deference to those who are likely to
benefit (utilitarianism). Some suggest that patients with a
life expectancy of less than five years should not be con-
sidered for transplantation as they are not likely to derive
significant benefit [1]. A Canadian recommendation is not
to evaluate individuals who are unlikely to survive the wait
period [2]. Some would argue that anyone who might
benefit regardless of the risk should have equal access to* Correspondence: Bryce.kiberd@dal.ca
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stated.kidney transplantation. Most agree that excluding trans-
plantation based solely on age is unjust [3].
There is considerable variation in the wait list as a
percentage of those on dialysis between countries, within
countries and within regions [4]. There no clear explan-
ation of this variation and many believe that eligibility
for listing is not transparent and worthy of further evalu-
ation [5]. On a patient level, being able to predict who is
likely to be harmed and who is likely to benefit is
unclear. Some of the confusion has been generated by
the belief that since all patient groups that are trans-
planted have a net benefit in life years gained (even for
those aged 70+), transplantation is being denied to many
that would benefit [6,7].
A detailed analysis of the patient survival demonstrates
that there is an increased risk of early death among
transplanted patients compared to those remaining on
the wait list [7,8]. The magnitude and duration of
increased risk may vary by organ source (live versus
deceased), recipient age and organ quality. Generally,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Figure 1 Modeled survival of transplant compared to wait list
cohorts.
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patients survive the first six months, transplantation
appears to benefit most.
However there are several caveats that bear scrutiny.
Many on the transplant wait list are on hold and these
patients are not transplanted. Those on hold/inactive
have recently been shown to have a 2.2-fold greater risk
of death than those who are active [9]. Since earlier
studies did not adjust for this, the net benefit has been
significantly overestimated. In addition, high wait list
mortality coupled with long wait times means that a
significant proportion will die on the wait list [10]. For
those that die or are removed from the list, there will be
needless expense and intrusiveness of evaluation and re-
testing annually without benefit. Lastly, even though the
period of increased risk is relatively short (< six months),
the time to equal percent survival (intersection of the
two survival curves), and equal cumulative life years is
progressively longer. For example, in elderly patients
aged 70+, the period to equal risk was 125 days, but the
time to equivalent percent survival was > 1.5 years [7].
No study has calculated the time to equivalent life years
(area under the curves), which likely occurs > 2.5 years
post transplantation in patients with higher mortality
rates. Theoretically, patients who are on the list can have
no benefit (die on the list), be harmed (receive a trans-
plant but die before those who were never transplanted),
or benefit (receive a transplant and outlive wait listed
patients). It is mathematically possible to derive the like-
lihood an individual is to terminate in one of these out-
comes (‘no benefit', ‘harm', and ‘benefit’) based on their
inherent mortality rate. The purpose of this study is to
examine how likely it is that a patient will be harmed
compared to benefit assuming all patients expose them-
selves to an initial increased risk with transplantation.
Rather than calculate a net benefit in life years, the
premise is that there will be a mortality rate, above
which, those who are transplanted are more likely to be
harmed than to benefit on a proportion basis. Arguably,
individuals with such a high mortality rate should not
proceed to transplantation.
Methods
Previous observational studies which have examined age
stratified cohorts of patients on the wait list have calcu-
lated the net benefit of transplantation by comparing
survival of those transplanted to those who remained on
the list. The analysis assumed that those transplanted
and those remaining on the wait list were equivalent
patients. The calculation of net benefit assumed that that
the comparator group (versus the transplanted group)
remained on the wait list until death [6-8]. Patients put
on hold were not transplanted but remained in the wait
listed cohort and those that were removed from the listfor illness were censored. The study by Rao et al., specific-
ally examined an older cohorts of patients aged 70+ years
[7]. In their study, the four year survival was 51% for the
wait list cohort and 66% for the transplant cohort; how-
ever, the survival for the transplant cohort was inferior to
the wait list cohort up until 1.5 to 2 years post follow up.
To describe this phenomenon, they demonstrate an initial
period of increased mortality risk that gradually tapers
to a reduced relative mortality for the transplant cohort
over time relative to the non-transplant cohort. It is not
clear from their methods, but they likely assumed
mortality rates were stable in their long-term calculation
of net benefit.
For this paper’s model, we assume there are three
periods of relative risk: a period of increased risk (for the
first 0.2 years), a period of equal risk for the remaining
first year, and a period of reduced mortality risk for the
transplanted cohort relative to the wait list group after
one year. Relative risks were generated to model actual
survival with time to equal percentage survival between
1.5 to 2 years, and overall survival of 66% for trans-
planted patients and 51% survival for those on the list at
year 4 (Figure 1) as demonstrated by the actual survival
for the cohort described by Rao et al. [7]. The survival
model assumed a simple exponential decline and mortality
rates (MR) in deaths per 100 patient years were converted
to a survival probability:
(exp^(−MR*t)), where t is equal to time in years.
We found that assuming an increased risk period of
0.2 years with a relative risk of 2.26, followed by 0.8 years
of equivalent risk and then a reduced risk of 0.44 pro-
duced a four year survival of 66% for the transplanted
cohort and 51% for the wait list cohort, with a time to
equal percent survival of 1.6 years.
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tients were of a certain age but rather examined theoret-
ical cohorts with similar mortality rates and compared
survival assuming a group was transplanted and a group
remained on the wait list until death. This initial analysis
assumes all are equivalent candidates, none are on hold
and there are no drop outs. A range of mortality rates
(deaths per 100 patient years) was then examined in in-
crements of five starting at 15 and progressing to 35
deaths per 100 patient years. We assumed that mortality
rates were fixed over time for individuals with the same
baseline mortality rate. For each death rate, the time to
equal cumulative life years was calculated as the time at
which the area under the survival curves for the wait list
cohort and transplant cohort was equal (Figure 1). This
time was calculated by integrating the area under the
survival curves (see Additional file 1). The percent sur-
vival in the transplanted group at the time of equal cu-
mulative life years was used to determine the transition
from ‘harm’ to ‘benefit’. To simplify the baseline model,
we assumed that all patients waited exactly two years on
the list. In addition, analyses with three and four years
on the wait list were performed. Figure 2 shows visually
how the percentages for ‘no benefit', ‘harm’ and ‘benefit’
were derived.
Unfortunately, some patients on the wait list are on hold
and these have recently been shown to have 2.2-fold
higher mortality rates [9]. Since hold patients are not
transplanted but are averaged in with those that are eli-
gible, those that are transplanted have a proportionately
lower mortality rate. By including non-transplantable
patients in the wait list cohort, previous estimates of the
net benefit of transplantation are overestimates. In an
additional sensitivity analysis, wait list inactivity was
incorporated into the model. Adjustments were made
to assume that 10% or 20% of the wait list were ineli-
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Figure 2 Graphic description of ‘no benefit’, ‘benefit’ and ‘harm’.mortality was thereby reduced. This adjustment results
in an increase in the mortality hazard ratio during the
increased risk period and reduces the net benefit in the
long term. For example, if 20% of the cohort is on hold,
the true relative risk during the increased mortality risk
period is 2.8 (versus 2.26) and the period of reduced
relative mortality risk is 0.55 (versus 0.44) for those
transplanted relative to the wait list cohort. Given the
relatively small confidence interval for the increase risk
of wait list mortality for those on hold (2.21, 95% confi-
dence interval, 2.15, 2.28), an additional sensitivity analysis
on the magnitude of this risk was not performed [9].
Another way of reporting survival is to estimate life
expectancy rather than mortality rates. Based on our as-
sumption of exponential decline in survival, life expect-
ancy (area under the survival curve) is equal to 1/MR [10].Results
Patients with higher mortality rates show an increasing
likelihood of ‘no benefit’ and ‘harm’ and diminishing
likelihood of ‘benefit’ (Table 1). Assuming a mortality
rate of 35 deaths per 100 patient years, transplantation is
slightly more likely to harm (29%) than benefit (21%),
whereas the remaining 50% of the patients are predicted
to die on the wait list. A mortality rate of 28 deaths per
100 patient years is the rate where ‘harm’ and ‘benefit’
have similar probability for transplanted patients.
Assuming that 20% of patients are inactive on the wait
list with a 2.2-fold higher mortality rate, those that are
actually transplanted have lower baseline mortality rates
than the entire wait list reference cohort. Therefore the
true reference population wait list also has a lower mortal-
ity rate. Table 2 and Figure 3 now show that at a mortality
rate of 35 deaths per 100 patient years transplantation is
predicted to cause harm (35%) 2.4 times more likely
than benefit (15%). The mortality rate where the harm
is equivalent to the benefit is now 22 deaths per 100
patient years. This roughly translates to a life expectancy
of 4.5 years.Table 1 Relative percent of ‘no benefit’, ‘harm’, and







Harm (%) Benefit (%) Ratio harm/
benefit
15 (6.7 years) 26 22 52 0.43
20 (5 years) 33 25 42 0.61
25 (4 years) 39 27 33 0.83
30 (3.3 years) 45 28 27 1.1
35 (2.9 years) 50 29 21 1.4
aDoes not take into account removal off the wait list. Values were rounded
and may not add to 100%.
Table 2 Relative percent of ‘no benefit’, ‘harm’, and
‘benefit’ assuming a two-year waiting time and 20% of







Harm (%) Benefit (%) Ratio harm/
benefit
15 (6.7 years) 26 29 45 0.63
20 (5 years) 33 32 35 0.93
25 (4 years) 39 34 26 1.3
30 (3.3 years) 45 35 20 1.8
35 (2.9 years) 50 35 15 2.4
aDoes not take into account removal off the wait list. Values were rounded
and may not add to 100%.
Table 3 Relative percent of ‘no benefit’, ‘harm’, and
‘benefit’ assuming a three and four year waiting time









Harm (%) Benefit (%) Ratio harm/
benefit
15 (6.7 years)
3 year 36 25 39 0.63
4 year 45 20 33
20 (5 years)
3 year 45 27 29 0.93
4 year 55 22 23
25 (4 years)
3 year 53 27 20 1.3
4 year 63 22 15
30 (3.3 years)
3 year 60 26 14 1.8
4 year 70 19 11
35 (2.9 years)
3 year 65 25 11 2.4
4 year 75 18 8
aDoes not take into account removal off the wait list. Values were rounded
and may not add to 100%.
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any one time changes this equivalency rate to 26 deaths
per 100 patient years. Longer waiting time increases the
percentage likely to suffer no benefit (die on the list) and
reduces the absolute percentages for ‘harm’ and ‘benefit’.
However, the ratio of harm to benefit remains un-
changed. Table 3 shows that longer wait time increases
the percentage that will derive no benefit and diminishes
the percentage that shows benefit.
Discussion
The model shows that a significant proportion of pa-
tients with high mortality rates is not likely to live long
enough to receive a transplant and, more importantly, is
more likely to be harmed than to benefit. Not trans-
planting patients with life expectancies < five years (> 20
deaths per 100 patient years) seems to be a reasonable
recommendation based on the likelihood of greater
harm. Currently, 43% of patients ≥ 65 years of age on the
wait list are considered to be high risk (diabetes mellitus
or two of the following: ischemic heart disease, cerebral











0 2 4 6 8 10
WL Transplant
Years
No Benefit- Death on List
Time to equal life years
Benefit
Harm
Figure 3 ‘No benefit’, ‘benefit’, and ‘harm’ assuming hold wait
listed patients are not transplanted and have higher mortality
rates.vascular disease) and have an average mortality rate of
22 deaths per 100 patient years [8].
Longer wait times increase the probability of ‘no benefit’
(death on the list) and reduce the likelihood of ‘benefit’.
Therefore, centers with long wait times will devote more
time and resources evaluating patients that will never be
transplanted. This analysis did not take into account
removal from the list, which would also be responsible for
inefficiency. In the US, 46% of wait listed patients over the
age of 65 are never transplanted [11]. Not all die on the
list, and some are removed. One strategy is to delay evalu-
ation until patients have sufficient wait time where the
likelihood of transplantation is high. Transplant centers
with this strategy essentially ‘weed out’ the poor candi-
dates by attrition prior to evaluating for the wait list. In
some centers (including our own) with relatively short
wait times, the tendency is to be more utilitarian and to
test and retest to look for a contraindication to exclude
marginal patients. Tests and more tests add to inefficiency,
costs, and false expectations. It is conceivable that these
different evaluation strategies and center realities are
responsible for significant wait list number variations as a
proportion of those on dialysis when in fact the actual
number and characteristics of patients transplanted are
not different.
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are not readily available to clinicians to provide baseline
mortality rates. Recent studies on frailty have shown that
functional status, in addition to co-morbidities, may be
an important determinant of survival [12,13]. Many of
the elderly patients that are not referred and have no
absolute contraindication to transplantation are likely to
be frail and are more likely to be harmed from the trans-
plant surgery and immunosuppression than more robust
individuals. Although adding functional measures may
improve prognostication, absolute prediction for an indi-
vidual will never be 100%. Some have argued rather that
attempting to ‘quantify the amorphous', we should spend
more time discussing uncertainty [14]. Rather than say-
ing a patient has an absolute contraindication as if there
is certainty that the patient will be harmed with an inter-
vention, we might suggest the poor candidate is more
likely to be harmed than to benefit. Future research is
needed not only to improve prognostication, but also in
communicating uncertainty to the patient and the com-
munity. Ethically, this uncertainty is a more honest con-
struct than arguing a patient is either not a candidate
based on ‘do no harm’ (non-maleficence) or not a candi-
date based on a presumption of limited benefit (utilitarian-
ism). The overall aim is to promote being reasonable but
also transparent with the need for ongoing research and
reassessment of eligibility decisions [15].
This present analysis uses mortality rates to generate
time to equal cumulative life years from the time of
transplantation. Wolfe and Gill calculate time to equal
survival [6,8]. These are two different time points. Since
the survival curve for the transplant cohort is inferior to
wait list cohort up to this point, the overall life years
(area under the curve) favors the wait list at this point.
The time from transplant to the time of equivalent life
years is the more critical value.
This study did not calculate net benefits. Projections
of net benefit as currently calculated are derived from
relatively short follow up times projected over several
decades. For instance, the median follow up in the study
by Gill was less than three years [16]. The study by
Wolfe included patients from 1991 to 1997 [6]. Patient
mortality increases exponentially with age (Gompertz’s
law) and this needs to be taken into account when pro-
jecting patient survival beyond five years especially in
older subjects [17,18]. Long-term projected calculations
that assume constant mortality overestimate benefit.
However, follow up in these studies is likely to be suffi-
cient to calculate time to equal cumulative life years. In
addition, prior studies did not take into account hold sta-
tus of wait listed patients with higher mortality rates [9].
We did not specifically address cohorts with lower
mortality rates since the duration of relative risks for
transplantation (increased, equal and reduced) might bedifferent and more favorable to transplantation. How-
ever, even using this model and assuming many patients
on the transplant list have mortality rates of between 5
and 10 deaths per 100 patient years, 65 to 80% would be
predicted to benefit with a 10 to 17% probability of harm
with transplantation [16]. For pediatric recipients with
even lower mortality, the likelihood of benefit would
be greater. The probability of ‘harm’ and ‘no benefit’
collectively would approach 10% in this cohort, with
90% deriving benefit.
The model assumes that the period of increased risk
remains unchanged and the magnitude of this risk is
independent of mortality rate. Further sensitivity analysis
on the magnitude of risk or duration of risk for the
transplant cohort are problematic since changing one
variable will distort survival if adjustments are not made
in the remaining variables. There is some evidence that
the time of early increased risk is longer and the magni-
tude of the risk is higher with higher mortality rates. Gill
et al. recently show that the early peak mortality relative
risk (compared to the wait list) in a ‘low risk’ elderly co-
hort was about 1.7 for a standard donor organ whereas
the peak mortality relative risk in a ‘high risk’ elderly co-
hort was 2.5 [8]. Gill’s study also showed that the relative
mortality risk for expanded criteria donors (ECDs) was
even higher. Therefore, patients receiving ECDs will also
have relatively more harm than benefit compared to
non-ECD organs. Taking into account these factors di-
minishes the projected benefits and increases the likeli-
hood of harm to a greater extent than projected in this
theoretical analysis. Therefore, this analysis is overly
conservative in favor of transplantation. The model also
assumes that the mortality rate is fixed over time and
this is a necessary simplification. However, if the mortality
rate increases (or decreases if a comorbidity is reversed)
the higher (or lower) rate can then be used accordingly.
The analysis does not take quality of life into account,
nor does it take into account the pain and suffering
related to transplantation surgery and its complications.
A contrary argument is that patients should have a choice
to take a greater risk of early death for uncertain benefits.
This study shows that even in patients with high mortality
rates there will always be a small percentage that derives
benefit. Some individuals tend to be conservative in their
choice of risky interventions and may prefer an existing
health state to an uncertain outcome. This paper does not
address different individual levels of risk aversion or risk
loving. In addition, this is a simulation exercise to consider
an alternative perspective to the net benefit model, it is
not meant to be definitive. Future registry analysis of large
data sets using this approach would be useful. Finally, the
concept of ‘harm’ may be strong wording. In some cases
early death may be unavoidable and related neither to
dialysis nor transplantation.
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the elderly based on numbers needed to treat to prevent
death on the wait list [19]. Unfortunately their model
examined age rather than mortality rate, assumed time
to equivalent percent survival was the same as time to
equivalent life years and assumed that time to equivalent
survival did not change with increasing age. Nonethe-
less, their findings also suggest that the likelihood of
transplantation benefiting patients with reduced life
expectancies (whether from age or co-morbidity) is low
as demonstrated by large numbers needed to be treated
to prevent one death.
Conclusion
In summary this study challenges the premise that all
patients who are transplanted will benefit. Rather it pro-
poses that patients with a high inherent mortality rate
may be more likely to have their life reduced with a
transplant with a smaller probability that there would be
a net gain in life. Based on current survival models,
patients with mortality rates exceeding 20 to 25 deaths
per 100 patient years are at risk of potentially more
harm than good.
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